Ipamorelin was evaluated as a selective growth hormone secretagogue in in vitro studies, demonstrating its ability to selectively stimulate growth hormone release through specific receptor mechanisms. This in vitro research established ipamorelin’s biochemical selectivity compared to other growth hormone secretagogues available at that time. As an in vitro study, these findings demonstrate receptor-level activity but do not provide evidence regarding systemic effects or clinical outcomes in human subjects.